查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1790306

乾癬性關節炎治療市場規模、佔有率和趨勢分析報告：按藥物類別、類型、給藥途徑、地區和細分市場預測，2025 年至 2030 年

Psoriatic Arthritis Treatment Market Size, Share & Trends Analysis Report By Drug Class (NSAIDs, DMARDs, Biologics), By Type (Prescriptions, OTC), By Route Of Administration (Topical, Oral, Injectable), By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 110 Pages | 商品交期: 2-10個工作天內

價格

乾癬性關節炎治療市場摘要

2024 年全球乾癬性關節炎治療市場價值估計為 113.5 億美元，預計到 2030 年將達到 199.1 億美元，2025 年至 2030 年的複合年成長率為 9.8%。新產品的推出、前景看好的產品線、消費者意識的顯著提高以及疾病負擔的增加預計將成為推動市場成長的一些因素。

乾癬性關節炎是一種與銀屑病相關的慢性退化性疾病。如果不及時、適當地治療，該疾病可能導致不可逆的關節損傷。雖然確切的致病因素尚不清楚，但研究表明，近40%的病例與遺傳因素有關。

乾癬性關節炎有時會被誤診為類風濕性關節炎或痛風。然而，隨著消費者意識的提高，以及私人和公共機構組織的多項宣傳活動，預計誤診和誤治的發生率將降低。此外，治療費用的上漲以及部分藥物的副作用預計將抑制市場成長。

生物製藥的標靶作用和生物相似藥的出現，正在為銀屑病關節炎的治療帶來重大的模式轉移。然而，消費者對安全性和療效均有提升且經濟實惠的藥物的需求，可能會對市場動態產生正面影響。

改善新興市場的醫療基礎設施並擴大保險覆蓋範圍也至關重要。亞太和拉丁美洲國家正迅速改善其醫療體系，並擴大高成本生物製藥的可近性。隨著這些市場的成熟，它們為跨國和國內製藥商提供了新的機會，使其能夠覆蓋先前服務不足的人群。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章乾癬性關節炎治療市場變數、趨勢和範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 乾癬性關節炎治療市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章乾癬性關節炎治療市場：藥物類別估計和趨勢分析

  • 藥品類別細分儀表板
  • 乾癬性關節炎治療市場：藥物類別差異分析
  • 全球乾癬性關節炎治療市場規模及趨勢分析（依藥物類別，2018-2030 年）
  • NSAIDs
  • DMARD
  • 生物製藥
  • 其他

第5章乾癬性關節炎治療市場：類型估計和趨勢分析

  • 類型細分儀表板
  • 乾癬性關節炎治療市場：類型變異分析
  • 全球乾癬性關節炎治療市場規模及趨勢分析（2018-2030）
  • 處方箋
  • 非處方藥

第6章乾癬性關節炎治療市場：給藥途徑估計與趨勢分析

  • 給藥途徑細分儀表板
  • 乾癬性關節炎治療市場：給藥途徑變異分析
  • 全球乾癬性關節炎治療市場規模及趨勢分析（依給藥途徑，2018-2030 年）
  • 外用
  • 口服
  • 注射

第7章乾癬性關節炎治療市場：區域估計和趨勢分析

  • 區域市場儀表板
  • 2024 年及 2030 年區域市場佔有率分析
  • 各地區連續生物加工市場：關鍵要點
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第8章 競爭態勢

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商格局
    • Key company heat map analysis, 2024
  • 公司簡介
    • AbbVie Inc.
    • Amgen Inc.
    • Johnson &Johnson Services, Inc.
    • Bristol-Myers Squibb Company
    • Novartis AG
    • Eli Lilly and Company
    • Pfizer, Inc.
    • UCB SA
Product Code: GVR-2-68038-990-6

Psoriatic Arthritis Treatment Market Summary

The global psoriatic arthritis market size was estimated at USD 11.35 billion in 2024 and is projected toprojected to reach USD 19.91 billion by 2030, growing at a CAGR of 9.8% from 2025 to 2030. The new product launches, promising pipeline, a significant rise in consumer awareness, and increasing disease burden are some factors expected to fuel market growth.

Psoriatic arthritis is a chronic degenerative condition associated with psoriasis. In the absence of proper and timely treatment, the disease may lead to irreversible joint damage. Although the exact causative factors remain unknown, research suggests that nearly 40% of cases are attributable to genetic factors.

Psoriatic arthritis may be misdiagnosed as rheumatoid arthritis or gout. However, heightened consumer awareness, aided by multiple campaigns organized by private and public organizations, is likely to reduce the rates of misdiagnosis or incorrect treatment. In addition, the high cost of treatment and the adverse effects of some drugs are expected to restrain market growth.

There is a significant paradigm shift in the treatment of psoriatic arthritis, driven by the targeted action of biologics and the emergence of biosimilars. However, the consumer demand for cost-effective medicines with improved safety and efficacy profiles is likely to have a positive impact on market dynamics.

Healthcare infrastructure improvements and increased insurance coverage in emerging markets are also pivotal. Countries in Asia-Pacific and Latin America are witnessing rapid health system upgrades, enabling wider access to high-cost biologic therapies. As these markets mature, they present new opportunities for both multinational and domestic drug makers to tap into previously underserved populations.

Global Psoriatic Arthritis Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global psoriatic arthritis market report based on drug class, type, route of administration, and region:

  • Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
  • NSAIDs
  • DMARD
  • Biologics
  • Others
  • Type Outlook (Revenue, USD Million, 2018 - 2030)
  • Prescriptions
  • OTC
  • Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
  • Topical
  • Oral
  • Injectable
  • Regional Outlook (Revenue, USD Million, 2018 - 2026)
  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Spain
    • France
    • Italy
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Australia
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Type
    • 1.2.3. Route of Administration
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug Class outlook
    • 2.2.2. Type outlook
    • 2.2.3. Route of Administration
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Psoriatic Arthritis Treatment Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Psoriatic Arthritis Treatment Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Psoriatic Arthritis Treatment Market: Drug Class Estimates & Trend Analysis

  • 4.1. Drug Class Segment Dashboard
  • 4.2. Psoriatic Arthritis Treatment Market: Drug Class Movement Analysis
  • 4.3. Global Psoriatic Arthritis Treatment Market Size & Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
  • 4.4. NSAIDs
    • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. DMARDs
    • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Biologics
    • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Others
    • 4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Psoriatic Arthritis Treatment Market: Type Estimates & Trend Analysis

  • 5.1. Type Segment Dashboard
  • 5.2. Psoriatic Arthritis Treatment Market: Type Movement Analysis
  • 5.3. Global Psoriatic Arthritis Treatment Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 5.4. Prescriptions
    • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. OTC
    • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Psoriatic Arthritis Treatment Market: Route of Administration Estimates & Trend Analysis

  • 6.1. Route of Administration Segment Dashboard
  • 6.2. Psoriatic Arthritis Treatment Market: Route of Administration Movement Analysis
  • 6.3. Global Psoriatic Arthritis Treatment Market Size & Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
  • 6.4. Topical
    • 6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Oral
    • 6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Injectable
    • 6.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Psoriatic Arthritis Treatment Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Dashboard
  • 7.2. Regional Market Share Analysis, 2024 & 2030
  • 7.3. Continuous bioprocessing market by Region: Key Takeaways
  • 7.4. North America
    • 7.4.1. U.S.
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Canada
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. UK
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. Germany
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. France
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Italy
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. Spain
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Japan
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. China
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. India
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.4. Australia
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework/ reimbursement structure
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.5. South Korea
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework/ reimbursement structure
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Brazil
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Argentina
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. South Africa
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Regulatory framework/ reimbursement structure
      • 7.8.1.3. Competitive scenario
      • 7.8.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.2. Saudi Arabia
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework/ reimbursement structure
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.3. UAE
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Regulatory framework/ reimbursement structure
      • 7.8.3.3. Competitive scenario
      • 7.8.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. Key company heat map analysis, 2024
  • 8.4. Company Profiles
    • 8.4.1. AbbVie Inc.
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. Amgen Inc.
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. Johnson & Johnson Services, Inc.
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. Bristol-Myers Squibb Company
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. Novartis AG
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. Eli Lilly and Company
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. Pfizer, Inc.
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. UCB S.A.
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product benchmarking
      • 8.4.8.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 Global psoriatic arthritis treatment market, by region (USD Million) 2018 - 2030
  • Table 3 Global psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 4 Global psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 5 Global psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
  • Table 6 North America psoriatic arthritis treatment market, by country (USD Million) 2018 - 2030
  • Table 7 North America psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 8 North America psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 9 North America psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
  • Table 10 U.S. psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 11 U.S. psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 12 U.S. psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
  • Table 13 Canada psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 14 Canada psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 15 Canada psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
  • Table 16 Mexico psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 17 Mexico psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 18 Mexico surgical ablation market, by route of administration (USD Million) 2018 - 2030
  • Table 19 Europe psoriatic arthritis treatment market, by country (USD Million) 2018 - 2030
  • Table 20 Europe psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 21 Europe psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 22 Europe psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
  • Table 23 Germany psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 24 Germany psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 25 Germany psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
  • Table 26 UK psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 27 UK psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 28 UK psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
  • Table 29 France psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 30 France psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 31 France psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
  • Table 32 Italy psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 33 Italy psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 34 Italy psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
  • Table 35 Spain psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 36 Spain psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 37 Spain psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
  • Table 38 Asia Pacific psoriatic arthritis treatment market, by country (USD Million) 2018 - 2030
  • Table 39 Asia Pacific psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 40 Asia Pacific psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 41 Asia Pacific psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
  • Table 42 China psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 43 China psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 44 China psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
  • Table 45 Japan psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 46 Japan psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 47 Japan psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
  • Table 48 India psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 49 India psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 50 India psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
  • Table 51 South Korea psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 52 South Korea psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 53 South Korea psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
  • Table 54 Australia psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 55 Australia psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 56 Australia psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
  • Table 57 Latin America psoriatic arthritis treatment market, by country (USD Million) 2018 - 2030
  • Table 58 Latin America psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 59 Latin America surgical ablation market, by type (USD Million) 2018 - 2030
  • Table 60 Latin America laparoscopic ablation market, by route of administration (USD Million) 2018 - 2030
  • Table 61 Latin America percutaneous ablation market, by route of administration (USD Million) 2018 - 2030
  • Table 62 Latin America psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
  • Table 63 Brazil psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 64 Brazil psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 65 Brazil surgical ablation market, by route of administration (USD Million) 2018 - 2030
  • Table 66 Argentina psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 67 Argentina psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 68 Argentina surgical ablation market, by route of administration (USD Million) 2018 - 2030
  • Table 69 MEA psoriatic arthritis treatment market, by region (USD Million) 2018 - 2030
  • Table 70 MEA psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 71 MEA psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 72 MEA psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
  • Table 73 South Africa psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 74 South Africa psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 75 South Africa psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
  • Table 76 Saudi Arabia psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 77 Saudi Arabia psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 78 Saudi Arabia psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030
  • Table 79 UAE psoriatic arthritis treatment market, by drug class (USD Million) 2018 - 2030
  • Table 80 UAE psoriatic arthritis treatment market, by type (USD Million) 2018 - 2030
  • Table 81 UAE psoriatic arthritis treatment market, by route of administration (USD Million) 2018 - 2030

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Psoriatic arthritis treatment market: market outlook
  • Fig. 10 Psoriatic arthritis treatment competitive insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Industry value chain analysis
  • Fig. 15 Psoriatic arthritis treatment market driver impact
  • Fig. 16 Psoriatic arthritis treatment market restraint impact
  • Fig. 17 Psoriatic arthritis treatment market strategic initiatives analysis
  • Fig. 18 Psoriatic arthritis treatment market: Drug Class movement analysis
  • Fig. 19 Psoriatic arthritis treatment market: Drug Class outlook and key takeaways
  • Fig. 20 NSAIDs market estimates and forecast, 2018 - 2030
  • Fig. 21 DMARDs market estimates and forecast, 2018 - 2030
  • Fig. 22 Biologics market estimates and forecast, 2018 - 2030
  • Fig. 23 Others market estimates and forecast, 2018 - 2030
  • Fig. 24 Psoriatic arthritis treatment Market: Type movement Analysis
  • Fig. 25 Psoriatic arthritis treatment market: Type outlook and key takeaways
  • Fig. 26 Prescriptions market estimates and forecasts, 2018 - 2030
  • Fig. 27 OTC market estimates and forecasts,2018 - 2030
  • Fig. 28 Psoriatic arthritis treatment market: Route of Administration movement analysis
  • Fig. 29 Psoriatic arthritis treatment market: Route of Administration outlook and key takeaways
  • Fig. 30 Topical market estimates and forecasts, 2018 - 2030
  • Fig. 31 Oral market estimates and forecasts,2018 - 2030
  • Fig. 32 Injectable market estimates and forecasts, 2018 - 2030
  • Fig. 33 Global psoriatic arthritis treatment market: Regional movement analysis
  • Fig. 34 Global psoriatic arthritis treatment market: Regional outlook and key takeaways
  • Fig. 35 North America market estimates and forecasts, 2018 - 2030
  • Fig. 36 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 37 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 38 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 39 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 40 UK market estimates and forecasts, 2018 - 2030
  • Fig. 41 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 42 France market estimates and forecasts, 2018 - 2030
  • Fig. 43 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 44 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 45 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 46 China market estimates and forecasts, 2018 - 2030
  • Fig. 47 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 48 India market estimates and forecasts, 2018 - 2030
  • Fig. 49 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 50 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 51 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 52 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 53 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 54 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 55 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 56 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 57 UAE market estimates and forecasts, 2018 - 2030